Assignee
HANALL BIOPHARMA CO LTD
KR·10 granted patents·17 pending applications·58 citations·filing 2005–2024
Top patents by PatentIndex Score
27 records- 0192US7998469B2Protease resistant interferon beta mutantsHANALL BIOPHARMA CO LTD·Filed 2007·Granted Aug 16, 2011·14 cites·11 claims
- 0291US8052964B2Interferon-β mutants with increased anti-proliferative activityHANALL BIOPHARMA CO LTD·Filed 2008·Granted Nov 8, 2011·11 cites·12 claims
- 0390US7884073B2Modified growth hormoneHANALL BIOPHARMA CO LTD·Filed 2006·Granted Feb 8, 2011·14 cites·32 claims
- 0489US7998930B2Modified growth hormonesHANALL BIOPHARMA CO LTD·Filed 2005·Granted Aug 16, 2011·13 cites·12 claims
- 0587US2025026835A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2024·Application pending·0 cites
- 0684US10544226B2Antibody binding to FcRn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2015·Granted Jan 28, 2020·4 cites·21 claims
- 0784US2024092913A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0883US11613578B2Antibody binding to FCRN for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2019·Granted Mar 28, 2023·1 cites·23 claims
- 0981US2023235063A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1075US10336825B2Antibody binding to FcRn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2017·Granted Jul 2, 2019·1 cites·4 claims
- 1168US11926669B2Anti-FcRn antibody or antigen binding fragment thereof with improved stabilityHANALL BIOPHARMA CO LTD·Filed 2023·Granted Mar 12, 2024·0 cites·20 claims
- 1263US2019135917A1Antibody binding to fcrn for treating autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2019·Application pending·0 cites
- 1362US2025223362A1Anti-fcrn antibody or antigen binding fragment thereof with improved stabilityHANALL BIOPHARMA CO LTD·Filed 2023·Application pending·0 cites
- 1460US2011052683A1Pharmaceutical preparation for treating cardiovascular diseaseHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 1560US2011111021A1Pharmaceutical preparationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 1660US2011038931A1Composite preparationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 1752US2024287191A1Formulation for anti-fcrn antibodyHANALL BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1850US2024059768A1A stable ophthalmic composition comprising tanfanercept, which is free of stabilizer or substantially free of stabilizerHANALL BIOPHARMA CO LTD·Filed 2022·Application pending·0 cites
- 1950US2024059767A1Treatment of dry eye syndrome using an ophthalmic composition comprising tanfanerceptHANALL BIOPHARMA CO LTD·Filed 2021·Application pending·0 cites
- 2049US2014235558A1Pharmaceutical composition having activity of anticancerHANALL BIOPHARMA CO LTD·Filed 2013·Application pending·0 cites
- 2149US2011111022A1Pharmaceutical formulationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 2248US2011117194A1Pharmaceutical formulation containing angiotensin-ii receptor blockerHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 2344US10280207B2FcRn-specific human antibody and composition for treatment of autoimmune diseasesHANALL BIOPHARMA CO LTD·Filed 2014·Granted May 7, 2019·0 cites·5 claims
- 2444US2013071471A1Pharmaceutical composition for treating atopic dermatitisHANALL BIOPHARMA CO LTD·Filed 2012·Application pending·0 cites
- 2542US9580490B2Uses of modified human tumor necrosis factor receptor-1 polypeptideHANALL BIOPHARMA CO LTD·Filed 2013·Granted Feb 28, 2017·0 cites·13 claims
- 2640US2014377346A1Bosentan controlled release oral preparationHANALL BIOPHARMA CO LTD·Filed 2013·Application pending·0 cites
- 2735US2011212175A1Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitorHANALL BIOPHARMA CO LTD·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when HANALL BIOPHARMA CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →